Skip to main content

Dr Hayley McKenzie

MA MBBS MRCP PhD

Training and education

  • Trained in medicine at the University of Cambridge (pre-clinical), followed by King’s College London School of Medicine (clinical), qualified 2008
  • Foundation and core medical training posts in London hospitals (2008 to 2012)
  • Certificate in Medical Oncology (MRCP) 2016
  • PhD in Cancer Sciences, University of Southampton, 2021
  • Certificate of Completion of Training in Medical Oncology, 2023

Experience

Dr McKenzie is a medical oncologist. She first joined the Trust in 2013 as a specialty registrar and has been working as a consultant in breast cancer since 2023.

Dr McKenzie undertook specialist registrar training in medical oncology in Wessex, from 2013 to 2023. She has expertise in the management of early and late stage breast cancer. Her PhD research was in the area of triple negative breast cancer and immunology. She is morbidity and mortality lead for medical oncology. She set up the mainstream genetics service for breast cancer in Southampton.

Research

  • Pulmonary tumour thrombotic microangiopathy mimicking immunotherapy-associated pneumonitis. McKenzie H, Scott D, Bateman AC, De La Pena Gomez H. Sci Rep. 2023 Jul 25;13(1):11327. doi: 10.1038/s41598-023-36990-9.
  • The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research. Fittall M, Liu J, Platt J et al. Br J Cancer. 2023 Jun;128(11):1977-1980. doi: 10.1038/s41416-023-02251-9.
  • Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients. McKenzie HS, Maishman T, Simmonds P et al. Br J Cancer. 2020 May;122(11):1618-1629. doi: 10.1038/s41416-020-0784-z.
  • Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. McKenzie HS, Mead G, Huddart R et al. Clin Genitourin Cancer. 2018 Dec;16(6):458-465.e2. doi: 10.1016/j.clgc.2018.07.006.